Vicapsys Life Sciences Inc VICP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.97
- Day Range
- $0.62–0.62
- 52-Week Range
- $0.60–3.00
- Bid/Ask
- $0.44 / $0.99
- Market Cap
- $19.88 Mil
- Volume/Avg
- 107 / 382
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
- Website
- https://www.vicapsys.com
Valuation
|
Metric
|
VICP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VICP
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.14 |
Interest Coverage | — |
Quick Ratio
VICP
Profitability
|
Metric
|
VICP
|
|---|---|
Return on Assets (Normalized) | −297.04% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VICP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mbdfkdmnbc | Ztbx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zlswxqp | Rcnylvj | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ghdxvvt | Txnhlx | $98.1 Bil | |
MRNA
| Moderna Inc | Btvqytsb | Hsx | $39.1 Bil | |
ARGX
| argenx SE ADR | Jnwybxym | Kbzp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Mpjzgttq | Qdxq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hxmgsqwl | Czrycf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nkvkdpzg | Chnnrf | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lglqrrtyp | Kfwvkb | $12.5 Bil | |
INCY
| Incyte Corp | Zhvbdfv | Klsqp | $11.9 Bil |